Back to News
Sep 25, 2025 12:10 PM

PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles

PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.

PepGen on Wednesday released clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1).

Myotonic dystrophy is a rare, inherited genetic disorder characterized by progressive muscle weakness and myotonia, which is the inability of muscles to relax after a contraction.

It is a multisystemic condition affecting not only muscles but also the heart, brain, eyes, endocrine system, and other organs.

Also Read: PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

Data

FREEDOM Results for the 15 mg/kg (n=8) dose cohort, splicing and muscle concentration data:

Mean ...